Newsroom
Top Results
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
PDF Version Budget impact analysis published in the Expert Review of Ophthalmology journal MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of […]
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
PDF Version The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing […]
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
PDF Version Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) […]
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
PDF Version Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing […]
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
PDF Version Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused […]
Sight Sciences Announces 1,000th TearCare® Customer Installation
PDF Version Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended […]
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
PDF Version DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETING MEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHS MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform […]
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
*Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical Ophthalmology *Study authors concluded that the TearCare procedure delivered superior symptoms improvements over LipiFlow in patients suffering from advanced dry eye disease. These patients experienced significantly better symptoms improvements, quality of vision, and symptom frequency